Yes, like PYMX, AVXL is a classic example of poor management nearly sinking a promising drug. AVXL's new CEO is righting the ship, and because AVXL, like the failed PRAN before it, is NOT pursuing the same failed pathway that Big Pharma has exhausted, it possibly has an actual treatment for Alz. That's a discussion for the AVXL board (hint hint -- would like to see some of us posting there too). But, the brilliant move for AVXL is reminiscent of CTIX. By branching out to study the drug for seizures and Parkinson's, they're reducing the risk. This is similar to what CTIX did by buying the Brilacidin intellectual property, as well as having Prurisol.